Search results for "conservation."

showing 10 items of 1994 documents

The use of zoledronic acid in patients with bone metastases from prostate carcinoma: Effect on analgesic response and bone metabolism biomarkers

2005

Zoledronic acid is a bisphosphonate that is effective in the treatment of complications of metastatic bone disease. We have carried out a perspective study on 24 consecutive patients with prostate cancer metastatic to bone to verify the effect of zoledronic acid on analgesic response and a possible relationship with the levels of bone metabolism biomarkers. Eligibility for this study required prostate cancer patients with metastatic bone disease and pain not controlled by analgesics. Patients were excluded from the study if they were receiving cytotoxic chemotherapy or radiation therapy within three months. Eighteen patients (75%) were considered responder to acid zoledronic, only 6 patient…

Malemedicine.medical_specialtyBone diseasemedicine.medical_treatmentPainBone NeoplasmsGastroenterologyBone resorptionBone remodelingProstate cancerzoledronic acidInternal medicinemedicineHumansPharmacology (medical)Bone ResorptionInfusions Intravenousbone metastaseAgedPain MeasurementPharmacologyBone Density Conservation AgentsDiphosphonatesbusiness.industryImidazolesProstatic NeoplasmsMiddle AgedBisphosphonatemedicine.diseaseprostate cancerSurgeryRadiation therapyBone Density Conservation AgentsInfectious DiseasesZoledronic acidOncologybone metabolism biomarkerbusinessBiomarkersmedicine.drug
researchProduct

Progress of instability in fragility fractures of the pelvis: An observational study.

2019

Abstract Fragility fractures of the pelvis (FFP) are an increasing entity among elderly persons. Characteristics are different from high-energy pelvic trauma. Little is known about the natural course of FFP in conservative and after operative treatment. Materials and methods Medical charts and radiologic data of 148 patients with an FFP, who were admitted in a 3-year period, were analysed retrospectively. Incidence and characteristics of fracture progression (FP) were noted. Results Patients presenting early after a traumatic event had more often non-displaced fractures, fractures with lower FFP Type classification and were more frequently treated conservatively. FP was observed in 21 cases…

Malemedicine.medical_specialtyConservative Treatment03 medical and health sciencesFracture Fixation Internal0302 clinical medicineElderly personsMedicineHumansPelvic BonesFracture typePelvisGeneral Environmental ScienceAgedRetrospective Studies030222 orthopedicsNatural courseBone Density Conservation Agentsbusiness.industryIncidence (epidemiology)030208 emergency & critical care medicineMiddle AgedSurgeryPelvic traumamedicine.anatomical_structureTreatment OutcomeGeneral Earth and Planetary SciencesObservational studyFemalebusinessTomography X-Ray ComputedOperative fixationOsteoporotic FracturesInjury
researchProduct

Assessing the risk of osteonecrosis of the jaw due to bisphosphonate therapy in the secondary prevention of osteoporotic fractures

2012

There is evidence that the use oral bisphosphonates can lead to osteronecrosis of the jaws (ONJ). Although the occurrence of ONJ appears rare among oral bisphosphonates (BPs) users, it is important to know that it exists and can be opportunely minimized. INTRODUCTION: The purpose of this study is to evaluate the association between BPs prescribed for the secondary prevention of osteoporotic fractures and the occurrence of ONJ. METHODS: An Italian record linkage claims database with a target population of around 18 million individuals (6 million over 55 years of age) constituted the data source. We conducted a nested case-control study within a cohort of individuals aged 55+ years old, who w…

Malemedicine.medical_specialtyEndocrinology Diabetes and MetabolismONJDentistryOsteoporosis; fractures; biphosphonatesAdministration OralBisphosphonates Nested case–control study Osteonecrosis of the jaw Osteoporotic fracturesOSTEPOROSISRisk AssessmentAssociationADMINSTRATIVE DATABASESnested case-control studySettore MED/28 - Malattie OdontostomatologicheClaims dataMedicineHumansnested case-control study; osteoporotic fractures; osteonecrosis of the jaw; bisphosphonatesWomenbisphosphonatesAgedSecondary preventionAged 80 and overOral bisphosphonatesBone Density Conservation AgentsDiphosphonatesbusiness.industryMiddle Agedmedicine.diseaseOral BisphosphonateNecrosiosteonecrosis of the jawItalyClaims DataCase-Control StudiesOrthopedic surgeryBisphosphonates; Osteonecrosis of the jaw; Osteoporotic fractures; Nested case-control studyBisphosphonate-Associated Osteonecrosis of the JawFemaleSurgeryProfileBisphosphonate therapyMedical Record LinkagebusinessOsteonecrosis of the jawOsteoporotic Fractures
researchProduct

A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid…

2017

Background The aim of this study was to evaluate the incidence and the risk factors of osteonecrosis of the jaw (ONJ) in a group of patients treated with zoledronic acid (ZA) for bone metastases from solid tumors and enrolled in a preventive dental program. Material and Methods This 5-year retrospective longitudinal study included all consecutive oncological patients who underwent at least one infusion with ZA between 2004 and 2011 for bone metastases due to solid neoplasms. Results Of the 156 patients enrolled in the study, 17 developed ONJ (10.89%). At the multivariate analysis, severe periodontal disease (P=0.025), tooth extraction (P<0.0001) and starting the preventive dental program af…

Malemedicine.medical_specialtyLongitudinal studyTime FactorsBone NeoplasmsZoledronic Acid03 medical and health sciences0302 clinical medicinestomatognathic systemRisk FactorsmedicineHumansIn patientLongitudinal StudiesGeneral DentistryAgedRetrospective StudiesBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industryIncidence (epidemiology)ResearchIncidenceImidazolesRetrospective cohort study030206 dentistryMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseMedically compromised patients in DentistrySurgeryBone Density Conservation Agentsstomatognathic diseasesZoledronic acidOtorhinolaryngology030220 oncology & carcinogenesisUNESCO::CIENCIAS MÉDICASSurgeryBisphosphonate-Associated Osteonecrosis of the JawFemaleOsteonecrosis of the jawbusinessmedicine.drugMedicina oral, patologia oral y cirugia bucal
researchProduct

Oral bisphosphonate-related osteonecrosis of the jaws: Clinical characteristics of a series of 20 cases in Spain

2011

Objective: The objective of this study was to define the clinical characteristics of osteonecrosis of the jaws (ONJ) induced by oral bisphosphonates in a series of patients from a circumscribed area in northwest Spain. Study Design:A retrospective multicentre study was undertaken in 3 hospitals in an area with a radius less than 100 km in the Autonomous Community of Galicia (Spain). The medical records were reviewed and an oral examination was performed of patients diagnosed with oral bisphosphonate-related ONJ in the previous 3 years. Results: We detected 20 cases of ONJ (24 lesions) related to oral bisphosphonates (alendronate [16 patients] and ibandronate [4 patients]), which were mainly…

Malemedicine.medical_specialtyOsteoporosisCorticosteroid treatmentDiabetes mellitusmedicineHumansStage (cooking)Ibandronic AcidGeneral DentistryAgedRetrospective StudiesAged 80 and overSeries (stratigraphy)Oral Medicine and PathologyOral bisphosphonatesAlendronateBone Density Conservation AgentsDiphosphonatesbusiness.industryMedical recordMiddle Aged:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseSurgeryOtorhinolaryngologySpainUNESCO::CIENCIAS MÉDICASOral examinationBisphosphonate-Associated Osteonecrosis of the JawFemaleResearch-ArticleSurgerybusinessMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Zoledronic acid induces a significant decrease of circulating endothelial cells and circulating endothelial precursor cells in the early prostate can…

2012

&lt;b&gt;&lt;i&gt;Purpose:&lt;/i&gt;&lt;/b&gt; Published data demonstrated that zoledronic acid (ZOL) exhibits antiangiogenetic effects. A promising tool for monitoring antiangiogenic therapies is the measurement of circulating endothelial cells (CECs) and circulating endothelial precursor cells (CEPs) in the peripheral blood of patients. Our aim was to investigate the effects of ZOL on levels of CECs and CEPs in localized prostate cancer. &lt;b&gt;&lt;i&gt;Methods:&lt;/i&gt;&lt;/b&gt; Ten consecutive patients with a histologic diagnosis of low-risk prostate adenocarcinoma were enrolled and received an intravenous infusion of ZOL at baseline (T0), 28 days (T28) and 56 days (T56). Blood samp…

Malemedicine.medical_specialtyPathologyCancer ResearchBone Density Conservation AgentAngiogenesismedicine.medical_treatmentUrologyAngiogenesis InhibitorsAngiogenesis; Circulating endothelial cells; Circulating endothelial precursor cells; Prostate cancer; Zoledronic acid; Aged; Angiogenesis Inhibitors; Bone Density Conservation Agents; Cell Movement; Diphosphonates; Endothelial Cells; Humans; Imidazoles; Male; Middle Aged; Neoadjuvant Therapy; Prostatic Neoplasms; Stem Cells; Medicine (all); Oncology; Cancer ResearchFlow cytometryProstate cancerCirculating endothelial cellCell MovementStem CellPrecursor cellMedicineHumansImidazoleNeoadjuvant therapyZoledronic acidAgedEndothelial CellProstate cancermedicine.diagnostic_testBone Density Conservation AgentsDiphosphonatesbusiness.industryStem CellsMedicine (all)ImidazolesEndothelial CellsProstatic NeoplasmsGeneral MedicineMiddle Agedmedicine.diseasePeripheral bloodNeoadjuvant TherapyAngiogenesiZoledronic acidDiphosphonateOncologyCirculating endothelial precursor cellProstatic NeoplasmStem cellbusinessmedicine.drugAngiogenesis InhibitorHuman
researchProduct

Prescription of anti-osteoporosis medications after hospitalization for hip fracture: a multicentre Italian survey.

2017

Purpose: Literature data indicate that the proportion of patients with recent hip fracture who receive a prescription for anti-osteoporotic drugs is low and does not seem to increase over time. This study aimed to obtain data on the prescription for anti-osteoporotic drugs in Italian patients discharged after a recent hip fracture and to assess which variables could have influenced the decision for prescribing osteoporosis medication. Methods: A total of four Italian centres located in four different geographical areas (Siena, Verona, Naples and Palermo) participated in this retrospective study. In each centre, experienced clinicians gathered the data of up to 200 consecutive patients disch…

Malemedicine.medical_specialtyPediatricsHip fracture; Anti-osteoporotic drugs; Comorbidities; Ca/vitamin D supplementsAgingAnti-osteoporotic drugs; Ca/vitamin D supplements; Comorbidities; Hip fractureAnti-osteoporotic drugOsteoporosisAlternative medicine030209 endocrinology & metabolismComorbiditiesHip fracture03 medical and health sciences0302 clinical medicineSex FactorsSurveys and QuestionnairesmedicineHumans030212 general & internal medicineMedical prescriptionPractice Patterns Physicians'AgedRetrospective StudiesAged 80 and overHip fractureBone Density Conservation AgentsGeriatrics gerontologybusiness.industryHip FracturesSettore MED/34 - Medicina Fisica E RiabilitativaRetrospective cohort studyMean ageMiddle Agedmedicine.diseaseCa/vitamin D supplementsHospitalizationAnti-osteoporotic drugsItalyAnti osteoporosisPhysical therapyAnti-osteoporotic drugs; Ca/vitamin D supplements; Comorbidities; Hip fracture; Aging; Geriatrics and GerontologyOsteoporosisFemaleCa/vitamin D supplementComorbiditieGeriatrics and GerontologybusinessOsteoporotic FracturesAging clinical and experimental research
researchProduct

A multicenter observational study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network …

2020

Background Incidence of Medication-Related Osteonecrosis of the Jaw (MRONJ) related to cancer and myeloma treatments is undetermined, with scarce data varying from 2 to 7.8/million/year in limited investigated populations. A 9-years [2009-2018] regional-wide survey was conducted, deploying the North-Western Italy Cancer Network (“Rete Oncologica Piemonte e Valle d’Aosta”), to assess number and main characteristics of MRONJ cases among myeloma/cancer patients, within a population of 4.5 million inhabitants. Material and Methods MRONJ cases were collected retrospectively from January 2009 to June 2015; from July 2015 to December 2018, data were collected prospectively. Number of new MRONJ cas…

Malemedicine.medical_specialtyPopulation03 medical and health sciencescheek refinement0302 clinical medicineBreast cancerplasticInternal medicinemedicineCarcinomaHumanseducationGeneral DentistryUNESCO:CIENCIAS MÉDICASRetrospective Studiesbuccal fat padeducation.field_of_studyOral Medicine and PathologyBone Density Conservation AgentsDiphosphonatesbusiness.industryResearchIncidence (epidemiology)Cancer030206 dentistrymedicine.diseaseDenosumabZoledronic acidItalyOtorhinolaryngologyaestheticsfacial silhouette refiningbuccal fat pad excisionBisphosphonate-Associated Osteonecrosis of the JawSurgeryMultiple MyelomaOsteonecrosis of the jawbusinessmedicine.drugMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zole…

2008

Abstract Background In addition to other treatments, patients with prostate cancer (pCA) and bone metastasis receive bisphosphonates. Since 2003, a previously unknown side-effect of bisphosphonates—bisphosphonate-associated osteonecrosis of the jaws (BP-ONJ)—has been described, and frequency has since increased. An exact incidence is still unknown. Objectives The aim of this study was to assess the incidence and additional factors in the development of BP-ONJ. Design, setting, and participants From July 2006 to October 2007, patients with advanced pCA and osseous metastasis receiving bisphosphonate therapy in the Department of Urology or Haematology and Oncology at the Johannes-Gutenberg-Un…

Malemedicine.medical_specialtyUrologymedicine.medical_treatmentBone NeoplasmsZoledronic AcidProstate cancerRisk FactorsInternal medicineGermanymedicinePrevalenceHumansProspective cohort studyAgedRetrospective StudiesBisphosphonate-associated osteonecrosis of the jawBone Density Conservation AgentsDiphosphonatesbusiness.industryIncidence (epidemiology)ImidazolesOsteonecrosisBone metastasisProstatic NeoplasmsRetrospective cohort studyBisphosphonateMiddle Agedmedicine.diseasePrognosisSurgeryZoledronic acidCross-Sectional StudiesInjections IntravenousbusinessJaw Diseasesmedicine.drugFollow-Up StudiesEuropean urology
researchProduct

Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patients

2010

Abstract Background Bisphosphonate-associated osteonecrosis of the jaws (BP-ONJ) is an adverse effect of bisphosphonate treatment with varying reported incidence rates. Methods In two neighboring German cities, prevalence and additional factors of the development of BP-ONJ in multiple myeloma patients with bisphosphonates therapy were recorded using a retrospective (RS) and cross-sectional study (CSS) design. For the RS, all patients treated from Jan. 2000 - Feb. 2006 were contacted by letter. In the CSS, all patients treated from Oct. 2006 - Mar. 2008 had a physical and dental examination. Additionally, a literature review was conducted to evaluate all articles reporting on BP-ONJ prevalen…

Malemedicine.medical_specialtylcsh:Specialties of internal medicineTreatment outcomeClinical NeurologyBisphosphonate-Associated Osteonecrosisstomatognathic systemlcsh:RC581-951medicinePrevalenceHumansAdverse effectGeneral DentistryMultiple myelomaAgedRetrospective StudiesAged 80 and overBone Density Conservation AgentsDiphosphonatesbusiness.industryDentistry(all)ResearchOsteonecrosisRetrospective cohort studyMiddle Agedmedicine.diseaseDermatologySurgerystomatognathic diseasesCross-Sectional StudiesTreatment OutcomeOtorhinolaryngologyOral and maxillofacial surgeryHead and neck surgeryFemaleNeurology (clinical)businessMultiple MyelomaBisphosphonate treatmentHead & Face Medicine
researchProduct